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BACKGROUND: Aging per se is a risk factor for reduced cardiac function and heart diseases, even when adjusted for aging-associated cardiovascular 
risk factors. Accordingly, aging-related biochemical 
and cell-biological changes lead to pathophysiological 
conditions, especially reduced heart function and heart 
disease.
CONTENT: Telomere dysfunction induces a profound 
p53-dependent repression of the master regulators of 
mitochondrial biogenesis and function, peroxisome 
proliferator-activated receptor gamma coactivator (PGC)-
1a  and PGC-1b  in the heart, which leads to bioenergetic 
compromise due to impaired oxidative phosphorylation and 
ATP generation. This telomere-p53-PGC mitochondrial/
metabolic axis integrates many factors linked to heart 
aging including increased DNA damage, p53 activation, 
mitochondrial, and metabolic dysfunction and provides 
a molecular basis of how dysfunctional telomeres can 
compromise cardiomyocytes and stem cell compartments in 
the heart to precipitate cardiac aging. 
SUMMARY: The aging myocardium with telomere 
shortening and accumulation of senescent cells restricts the 
tissue regenerative ability, which contributes to systolic or 
diastolic heart failure. Moreover, patients with ion-channel 
defects might have genetic imbalance caused by oxidative 
stress-related accelerated telomere shortening, which may 
subsequently cause sudden cardiac death. Telomere length 
can serve as a marker for the biological status of previous 
cell divisions and DNA damage with inflammation and 
oxidative stress. It can be integrated into current risk 
prediction and stratification models for cardiovascular 
diseases and can be used in precise personalized treatments.
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Abstract
Introduction
Besides resulting in continues functional and structural 
decrease of multiple organs, aging is also inventing some 
profound effects on heart and the arterial system. Age-
related cardiac and vascular changes include impaired 
endothelial function and intimal proliferation (1), increased 
arterial stiffness (2-7), left ventricular (LV) diastolic 
dysfunction (8-10), LV pathological hypertrophy (11), 
diminished LV systolic reverse capacity (9,10), decreased 
heart rate variability (12-14), and a reduction in maximal 
heart rate (15). Furthermore, as a consequence of aging, the 
interaction between the heart and arterial system is altered 
to preserve ventricle-arterial homeostasis.(16)
 As people grow older, the prevalence of cardiovascular 
disease (CVD) is increasing dramatically. More than 80% of 
cases of coronary artery disease (CAD) and 75% of cases 
of congestive heart failure (CHF) are found in geriatric 
patients. The incidence of CVD cases, which includes CAD, 
CHF, and also stroke, are found in 4 out of 1000 person/
years in adult aged 45-54 years old. The number of this 
incidence raise to 10 cases out of 1000 person/years in adult 
aged 65-75 years old. And it just grow worse as someone 
aged ≥ 85 years old, as the number of incidence found to be 
are 75 cases out of 1000 person/years.(17) 
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 Aging is a big risk factor for CVDs, which are a major 
cause of chronic disability and the leading cause of death 
worldwide. The morbidity and mortality rates which are 
associated with CVDs remain high and cause a dreadful 
burden on the healthcare system, even after the advanced 
prevention and treatment of CVDs over the last two 
decades. As mentioned before, the prevalence of CVDs is 
increasing in the older population. This shows that CVDs 
in older population are a major healthcare challenge that 
should be focused on. A good understanding of the complex 
interaction between the aging process and CVDs is needed 
to develop a novel therapeutic target for older patients.(18)
 The aging heart is indicated by a faulty responsiveness 
to  stress and by a reduced efficiency of endogenous 
protective mechanisms (e.g., ischemic pre-conditioning 
and post-conditioning), resulting in increased vulnerability 
to injury.(19) As for now, the detail mechanism which is 
involved in the cardiac senescence still has not been fully 
known. But, the progressive accrual of macromolecular 
oxidative harm over the  lifetime  is invoked as a major 
factor.(20) Reactive oxygen species (ROS) are steadily 
created within cells by several enzymatic reactions, including 
those catalyzed by cyclooxygenases, nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, and xanthine 
oxidase; however, the bulk of ROS production occurs as 
a byproduct of mitochondrial oxidative phosphorylation 
(OXPHOS).(21)
 Several epidemiologic surveys have reported an 
association of short telomere length (TL) with CVD (22-25) 
and cardiovascular mortality (26-27). The Cardiovascular 
Health Study showed that each shortened kb pair of TL 
correlated to a threefold increased risk of myocardial 
infarction (MI) and stroke.(22) It was reported in one of 
the latest systemic review and meta-analysis that there is 
a stable positive association of decreased leukocyte TL 
(LTL) with cardiometabolic outcomes, where one standard 
deviation (SD) decrease in LTL was significantly related to 
a 21%, 24%, and 37% increased risk of stroke, myocardial 
infaction (MI), and type 2 diabetes mellitus (T2DM), 
respectively (5). 
Telomeres and Telomerase
telomeric DNA is composed of noncoding double-stranded 
repeats of G-rich tandem DNA sequences (TTAGGG in 
vertebrates) that are extended several thousand base pairs 
(10 to 15 kb in humans and 25 to 40 kb in mice) and end in a 
150 to 300 nucleotide 3  single-stranded overhang (G-strand 
overhang) (Figure 1).(28,29,30) Several specific proteins 
are related to telomeric DNA, some of those are telomerase 
and the telomeric repeat binding factors (TRF)1 and TRF2 
which directly bind to the TTAGGG repeat and interact with 
other factors composing large protein complexes regulating 
TL and structure.(31)
 TL is greatly variable among individuals with the 
same age. Already at birth, noticeable differences in TL 
can be found. Several studies have suggested that TL 
can be predicted by the TL of the parents. Heritability of 
TL has been estimated to be as high as 82%.(32) Several 
environmental factors are also associated with telomere 
length and possible telomere attrition rate. Most important 
are oxidative stress (33) and factors related to oxidative 
stress such as smoking (34) and UV radiation (35).
 The human telomerase is responsible for maintaining 
and elongating TL and consists of the telomerase RNA 
component (TERC) and telomerase reverse transcriptase 
(TERT), the catalytic component. To maintain TL, TERT 
uses the TERC as a template to synthesize new telomeric 
DNA repeats at a single-stranded overhang. Several cells 
such as germ cells, stem cells, hematopoietic progenitor 
cells, activated lymphocytes, and most cancer cells, possess 
a high level of telomerase activity to overcome telomere 
shortening and control limitless cell division. However, 
somatic cells generally have a low or undetectable level 
of telomerase activity with limited longevity. The TL and 
integrity are regulated through the interplay between the 
telomerase and shelterin proteins.(36) Telomerase activity 
decreases with age but increases markedly in response to 
injury.(37) The telomerase expression in the mammalian’s 
heart is small, yet functionally significant. Telomerase has 
a role in regulating tissue repair and regenerative, this is 
shown by a substantial increase in telomerase expression 
which was found in cardiomyocytes, endothelial cells and 
fibroblasts of cryoinjured adult mice hearts.(38)
 During the shortening process of telomere to its 
crucial length, the cell enters cellular senescence, starting a 
series of changes in the gene expression of replicative cell-
cycle inhibitors and inhibits proliferation, then eventually 
into apoptosis (39) as known as replicative senescence. It 
is known that senescent cells change their morphology and 
secretary phenotype in autocrine and paracrine patterns. The 
pattern of this active altered secretion has has been named 
Telomeres are special chromatin structures located at the ends 
of eukaryotic chromosomes that prevent the recognition of 
chromosomal ends as double-stranded DNA breaks, thereby 
protecting these regions from recombination and degradation 
and avoiding a DNA damage cellular response. The 
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Aging is Functional Decline of Telomeres, Mitochondria and Stem Cells
Mitochondria play important roles in a myriad of cellular 
processes including ATP production via oxidative 
phosphorylation, biosynthetic pathways, cellular redox 
homeostasis, ion homeostasis, oxygen sensing, signaling, 
Figure 1. Telomere organization.
(30) (Adapted with permission 
from American Heart Association).
as the senescence-associated secretory phenotype (SASP). 
They secrete interleukin (IL)-6 and IL-8, intercellular 
adhesion molecule 1 (ICAM-1), metalloproteases, monocyte 
attractants, plasminogen activator inhibitor 1 (PAI-1) 
and vascular endothelial growth factor (VEGF).(40,41) 
Senescent cells are partly responsible for inflammation and 
also promoting apoptosis, tissue remodeling, and repair 
through their SASP. Thus, chronic inflammation initiates 
a vicious cycle which enhances telomere dysfunction 
and the accumulation of senescent cells. Cell senescence 
provokes chronic inflammation and accelerates aging and 
the development of aging-associated diseases.(41)
 After each cell division, the length of the telomere 
shortens, and when a critical shortening is reached, the 
cell enters senescence or apoptosis.(42,43) Thus, TL is 
considered a marker of cell senescence and replicative 
capacity.(42,44) LTL represents the average TL across 
a heterogeneous population of leukocytes including 
monocytes, granulocytes and lymphocytes, and can serve as 
a biological marker of aging.(45)
and regulation of programmed cell death. Mitochondrial 
dysfunction is central to theories of aging, because age-
related changes of mitochondria are likely to impair a host 
of cellular physiological functions in parallel and contribute 
to the development of all common age-related diseases.(46)
 The original formulation of the mitochondrial theory 
of aging postulates that raised production of mitochondria-
derived ROS could effects in a several macromolecular 
oxidative modifications, which are a primary causal factor in 
the aging process and also in the development of age-related 
diseases.(47,48) Mitochondrial retrograde signaling is a 
pathway of communication from mitochondria to nucleus, 
which involves multiple factors that sense and transmit 
mitochondrial signals to alter nuclear gene expression. This 
cross-talk between mitochondria and the nucleus affects 
many cellular functions and is assumed to have a critical 
role in the aging process. There are multiple signaling 
cascades that involve the mitochondria, including release of 
ROS from the mitochondria, Ca2+ signaling, which activate 
downstream effectors pathways and transcription factors and 
the nutrient sensing mechanistic target of rapamycin (mTOR) 
pathway that regulates growth and cellular metabolism. 
Recent studies suggest that longevity is regulated by both 
cell-autonomous and non-autonomous mitochondrial stress 
pathways triggered by mild mitochondrial impairment.(49) 
According to this model, adaptive mitochondrial retrograde 
pathways relay mitochondrial stress signals to nucleus, 
activating genes involved in maintenance of mitochondrial 
integrity and cellular function.(46)
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 Human body has a great ability for extensive and 
sustained tissue renewal throughout a lifetime. Reservoirs 
of somatic tissue stem cells are responsible in maintaining 
this continuous self-renewal ability.(50,51) These tissue 
stem cells have garnered increasing attention in ageing 
and regenerative research given accumulating evidence 
that age-associated physiological decline, particularly in 
highly proliferative organs, parallels blunted proliferative 
responses and misdirected differentiation of resident tissue 
stem cells. Tissues have largely different levels of baseline 
proliferative activity and regenerative potential. In the high-
turnover tissues, it is known that the resident stem cells 
have the ability to generate great numbers of specialized 
cell progeny and thereby sustaining tissue cellularity and 
functionality over a lifetime. Intuitively, it would seem 
reasonable to posit that preserving an adequate pool of 
tissue stem cells with robust potential for renewal would 
be vital to maintaining organ function with advancing age. 
That kind of thought is supported by the premature ageing 
phenotypes observed in mice with conditional deletion of 
the genes encoding ataxia telangiectasia and Rad3-related 
(ATR), forkhead box O (FOXO) transcription factors, or 
ataxia telangiectasia mutated (ATM). These mice exhibit 
tissue stem-cell defects or diminished oxidative defense and 
ROS-induced stem-cell depletion.(52)
 The failure of stem/progenitor cell failure due to p53-
mediated cellular checkpoints may underlie compromise of 
highly proliferative organs. But this mechanism seems not 
enough to describe the profound physiological decrease in 
more quiescent tissues, for example, heart (cardiomyopathy) 
and liver (reduced detoxification capacity, glucose 
intolerance). These pathologies indicate that telomere 
dysfunction elicits a degenerative state via additional 
mechanisms beyond the classical senescence and apoptosis 
checkpoints.(53,54)
 Telomere-dysfunction-induced repression of the PGC 
network is associated with mitochondrial dysfunction as 
evidenced by compromised OXPHOS and respiration, 
decreased ATP generation capacity, and increased oxidative 
stress. Importantly, given evidence of non-telomere-related 
functions of TERT (55,56), this also demonstrated that, 
with onset of telomere dysfunction, TERC-/- mice (normal 
TERT expression) experience degenerative phenotypes 
indistinguishable of those in the TERT-/- model.(57,58) 
The indistinguishable mitochondrial and energy profiles of 
TERT and TERC models indicate that telomere dysfunction 
per se is the principal factor driving these phenotypes.(53) 
Multiple levels of evidence establish telomere dysfunction-
induced p53 represses PGC-1a and PGC-1b, thereby 
linking telomeres to mitochondrial biology, oxidative 
defense, and metabolism. This telomere-p53-PGC pathway 
expands our understanding of how telomere dysfunction 
may compromise organ function and contribute to age-
related disorders.(53)
 Figure 2 shows that the core telomere-p53 axis 
integrates well with almost all genetic elements proven 
to be important in the aging process of genotoxic stress 
model of ageing.(52) First, it accounts for the premature 
aging phenotypes common to both telomere-dysfunctional 
mice and those with germline p53 hyperactivation.(59,60) 
Secondly, it explains why mice lacking sirtuin (SIRT)1 or 
SIRT6, which are proteins that attenuate p53 activity, tend 
to develop premature aging (61). Third, it could account 
for the observed connections between mitochondria and 
key aging factors such as PGC-1α, PGC-1β and FOXO 
proteins. Mice null for each of the genes encoding these 
proteins experience accelerated tissue degeneration and 
Figure 2. A model of interaction between DNA damage, p53 
activation and mitochondrial dysfunction.(50) (Adapted with 
permission Nature Publishing Group, 2010). UV: ultraviolet; IR: 
infrared; BMI1: B lymphoma Mo-MLV insertion region 1.
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mitochondrial dysfunction. Integration of mitochondria into 
this core ‘axis of aging’ is supported by the premature aging 
conditions shared by telomere-dysfunctional or hyper-p53 
mice, as well as mice that have excessive mitochondrial 
DNA mutation or are deficient in PGC-1α or PGC-1β, 
which are the master regulators of mitochondrial biogenesis 
and metabolism (62-64), although the precise molecular 
basis for this commonality in premature ageing phenotypes 
remains to be elucidated.(52)
Cardiovascular Aging
With aging, cardiac function declines. Cardiac reserve, i.e., 
the difference between the peak cardiac pumping level and 
the normal baseline resting level, is reduced. Cardiomyocyte 
loss, left-ventricular hypertrophy, changes in ventricle 
chamber diameter, and an accumulation of extracellular 
matrix lead to reduced cardiac output, decreased left-
ventricular end-systolic pressure, fractional shortening, and 
decreased heart rate.(65-67) These facts clearly stress that 
the heart ages, indicating that the maintenance and repair 
potential of the heart is limited.
 Cardiac aging is a complex process which includes 
aging and deposition of extracellular matrix, aging of the 
coronary vasculature, aging of cardiac fibroblasts, and aging 
of the contractile apparatus of the heart.(68-70) Constituting 
the core of cardiac function and the contractile apparatus, 
cardiomyocytes display a number of physiological and 
morphological features, which are affected by the aging 
process, and these changes are thought to give rise to 
reduced cardiac function and heart disease.(71)
 In old cardiomyocytes, there is a general tendency 
towards: 1) a reduced ability to cope with stress, e.g., via 
reduced expression of heat shock proteins (HSP70) and 
anti-oxidative enzymes (hemeoxygenase-1), 2) reduced 
and altered function of the mitochondrial respiratory chain 
(e.g., reduced expression of cytochrome c oxidase), which 
causes electron leakage and oxidative damage, 3) increased 
stiffness and reduced contractility/decelerated relaxation, 
related  to  downregulation  of  sarcoplasmatic  reticulum 
Ca2+-ATPase, increased expression of cytoskeletal proteins, 
and a transcriptional switch (caused by de-differentiation) of 
contractile protein isoforms, e.g., from fast (type V1) to slow 
(type V3) myosin (72,73), and 4) a shift from proliferation 
and survival signaling towards cell death signaling (reduced 
expression of survivin, modulation of the Bcl2 rheostat 
towards a pro-apoptotic state).(74,75) Figure 3 shows the 
age-dependent changes to cardiovascular tissues. Both the 
heart and vasculature undergo numerous alterations during 
Figure 3. Age-dependent changes to cardiovascular tissues.(74) (Adapted with permission from American Heart Association).
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aging as a result of deregulation of molecular longevity 
pathways, leading to compromised function.(76)
 The molecular mechanisms involved allow time for 
accumulated damage to occur and include free radicals, 
advance glycation end-products, apoptosis and senescence. 
The accumulation of DNA damage and telomere attrition 
may increase cells’ senescence in tissues and organs, and 
decreasing their functions, providing an explanation for 
the lower threshold to express the clinical manifestation of 
heart failure.(77)
 The shortening of telomeres and telomere attrition has 
been shown to contribute crucially to a number of factors 
associated with cardiac aging like oxidative stress, and 
the finding of different telomeric lengths in old and young 
cardiomyocytes suggests that cell division and consequent 
telomeric shortening may play a role. As a matter of fact, 
old cardiomyocytes show a reduction in TL from 30 to 
15 kb.(31,78) The paradigm that all cardiomyocytes are 
terminally differentiated has been challenged. Recent 
experiments using human left ventricular myocardial cells 
and carbon-dating techniques have established that DNA 
of cardiomyocytes continues to be synthesized many years 
after birth, indicating that cells in the human heart do renew 
well into adulthood.(79) Nevertheless, cardiomyocyte DNA 
synthesis decreases with age. At the age of 25, a mathematical 
modeling predicts that cardiomyocyte renewal rate is around 
1%. Meanwhile at the age of 75, the cardiomyocyte renewal 
rate is 0.45%. Considering this turnover rate, at the age of 
50 years, 55% of the cardiomyocytes stay from the time 
around birth.(77)
 Therefore, some therapeutic strategies to boost 
myocardial function and outcome in CHF are crucially 
needed, and novel medicines are rapidly being introduced 
lately.(80-82) Telomere biology might be involved in the 
biology of aging and age-associated pathology. Telomeres 
are connected to the basic biology of aging and trigger 
cellular senescence.(77)
Telomeres, Mitochondria and Stem Cells in The Aging Heart
Morbidity and mortality rates associated with CVD continue 
to be high and remain a tremendous burden for the national 
health care system. In 2015 alone, CVD-related costs were 
estimated to be $155 billions.(83) A long-term solution 
to this social and health care crisis will require a better 
understanding of how aging per se drives cardiovascular 
decline. This solution would help to develop the effective 
preventive and therapeutic strategies. Telomeres, repetitive 
TTAGGG sequences at the ends of chromosomes, have 
been significantly involved in the aging process. It is 
known that short telomeres precipitate functional decline in 
different tissues, which includes the cardiovascular system. 
This is showed by many studies in humans with telomere 
maintenance disorders and telomerase knock-out mice have 
that have been done.(52) 
 The numbers of telomere lost during each cell division 
are different among people. Prior evidence showed that 
increased oxidative stress and chronic inflammation are 
related to higher telomere loss and accelerated telomere 
shortening.(33) Several common risk factors for CVD 
(84) such as smoking (34), diabetes mellitus (85), 
hypercholesterolemia (86), hypertension (87), obesity 
(88), physical inactivity (89), alcohol consumption (90) 
and psychosocial problems (91) have been associated with 
short TL. Telomere shortening process is associated with 
these risk factors through increased tissue inflammation and 
oxidative stress.(92-94) 
 Mechanistically, telomere dysfunction-driven tissue 
compromise is thought to be secondary to the activation 
of DNA damage signaling pathways that converge on 
p53, a central executor of the DNA damage response 
pathway.(95) The activation of p53 induces senescent 
and apoptosis pathways, particularly in stem cell and 
progenitor compartments of highly regenerative organs. The 
elimination of stem and progenitor cells is assumed to be the 
leading force in the development of tissue defects.(96) 
 Cardiovascular stem cells and cardiovascular 
progenitor cells are known to be insufficient to protect 
against cardiovascular disease in older individuals. Since 
new evidence suggests that cardiovascular stem cells and 
cardiovascular progenitor cells are subject to age-associated 
changes which impair their function, these changes may 
contribute to the dysregulation of endogenous cardiovascular 
repair mechanisms in the aging heart and vasculature.(97)
 Human endothelial cells and vascular smooth 
muscle cells (VSMC) express telomerase activity, which 
is drastically activated by mitogenic stimuli via a protein 
kinase C-dependent pathway (98), yet its activity declined 
with in vitro aging because of a decrease in expression of 
TERT, which cause the telomere shortening and cellular 
senescence.(99,100) Introduction of telomerase extends the 
lifespan of both endothelial cells and VSMCs (100-102), 
suggesting a critical role of telomere and telomerase in 
vascular cell senescence.(103)
 Atherosclerosis is a complex inflammatory process 
involving adaptive and innate immune mechanisms.(104-
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109) Some researches also associating short telomeres with 
atherosclerosis.(110) Endothelial cell dysfunction triggered 
by atherogenic stimuli (e.g., elevated plasma cholesterol 
level, hypertension, diabetes, and smoking) is of central 
importance in the pathogenesis of atherosclerosis. These in 
vitro studies resulting in the implication of telomeres and 
telomerase in endothelial cell function. In vivo, age-dependent 
telomere shortening has been reported in endothelial 
cells from iliac, thoracic, and coronary arteries.(102,111-
113) Once fatty streaks are formed, activated neointimal 
leukocytes produce a plethora of inflammatory mediators 
that contribute to atheroma growth by provoking excessive 
VSMC proliferation and migration.(104,105,113-115) 
Telomerase has been implicated as an important regulator 
of VSMC proliferation in vitro, because TERT activation 
extends the lifespan of cultured VSMCs and, conversely, 
telomerase inhibition abrogates VSMC proliferation in a 
dose-dependent manner.(98,99,116) Regulation of VSMC 
proliferation by targeting telomerase activity appears to 
be independent of telomere length, because VSMC growth 
arrest occurs early after telomerase inhibition (98,117) 
and telomerase expression alone is capable of rescuing 
Figure 4. Model of how telomere dysfunction and other pathways cause cardiac aging through either cellular or metabolic 
compromise.(94) (Adapted with permission from American Heart Association).
the senescent phenotype of human plaque VSMCs despite 
short telomeres.(118) A role of telomerase on the control of 
VSMC growth has been also proposed in vivo. Telomerase 
activation and telomere maintenance appear to be critical 
for increased VSMC hyperplastic growth in hypertensive 
rats.(119)
 A deficiency of mitochondrial energetics has been 
documented in human and experimental animals with 
heart failure (Figure 4).(120) Mechanisms may include 
mitochondrial biogenesis that does not keep up with 
the increasing demand (121), mitochondrial uncoupling 
and decreased substrate availability,(122) and increased 
mitochondrial DNA deletions.(123)
 Studies have demonstrated that telomere dysfunction-
activated p53 directly leads to mitochondrial and metabolic 
compromise through the repression of the master regulators 
of mitochondrial biogenesis and function, peroxisome 
proliferator-activated receptor gamma coactivator (PGC)-
1a and PGC-1b.(53) PGC repression is associated with 
a profound compromise in mitochondrial biogenesis 
and function and subsequent decline in ATP generation, 
indicating that a fundamental problem of energy maintenance 
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drives the aging process.(96) Another potentially important 
link between mitochondrial oxidative stress and vascular 
aging is the induction of apoptosis.(124) Oxidative stress 
in aging is associated with an increased rate of endothelial 
apoptosis (125,126), which may contribute to microvascular 
rarefaction impairing the blood supply of the heart (127) 
and the brain (128). Cerebrovascular endothelial cells are 
rich in mitochondria, and normal mitochondrial function 
is essential for  maintaining  the  integrity of the blood-
brain barrier.  On  the basis of the available data with 
mitochondrial inhibitors (129), we posit that age-related 
mitochondrial dysfunction may contribute to breakdown 
of the blood-brain barrier, promoting neuroinflammation in 
aging.(130)
 Lately, there has been an experimental evidence that 
associate the mitochondrial free radical and telomere-
shortening theories of aging.(53) These abnormalities are 
associated with p53-mediated repression of PGC-1a and 
PGC-1b, and their downstream targets, nuclear respiratory 
factor-1 (NRF-1) and mitochondrial transcription factor A 
(TFAM). Thus, age-related telomerase dysfunction might 
represent a primary instigator of mitochondrial decay, which 
in turn would cause the decrease of bioenergetic efficiency 
and increase of ROS production via sustained p53 activation 
and further repression of PGC signaling.(131)
 Optimal regulation of mitochondrial autophagy is 
crucial for the maintenance of cell homeostasis. This is 
especially true for cardiomyocytes because of their post-
mitotic nature and their high reliance on mitochondrial 
oxidative metabolism for energy supply. Over their lifespan, 
cardiac cells are exposed to a high burden of mitochondria-
derived oxidative damage, which cannot be diluted through 
cell proliferation. This shows that the maintenance of a 
healthy pool of mitochondria and the removal of damaged 
organelles are important to preserve cardiomyocyte 
function and viability. Autophagy supplies this essential 
homeostatic function. This suggests that optimization of the 
housekeeping function of autophagy may be harnessed as a 
therapeutic means against heart senescence.(21)
 Some dietary and lifestyle factors such as marine 
omega-3 fatty acid (132), antioxidants (133), vitamin intake 
(134), physical activity (90), and healthy lifestyle (135) were 
reported to decrease rates of LTL shortening. These factors 
might have roles in reducing ROS, inhibiting inflammation, 
increasing the activity of endothelial nitric oxide synthase 
(eNOS), and increasing telomerase activity. A human study 
also reported that alterations in comprehensive lifestyle 
significantly increased telomerase activity and consequently 
telomere maintenance ability in human immune system 
cells.(135) Consequently, telomere shortening can be 
used as a reflection of cellular aging and a marker of the 
health status of the aging population.(136) Absolute TL at 
birth is determined by genetic materials from both parents. 
During the process of aging, the mean TL declines with cell 
replication and turnover. The process of telomere shortening 
is accelerated by the exposure to disease-promoting 
factors, such as smoking, obesity, and psychosocial stress. 
Furthermore, the activation of telomerase has been assumed 
as a possible target for reversing the telomere shortening.
(18) Figure 5 shows the relation of telomere length to CVD.
 In patients with CAD, LTL can be used as a prognostic 
tool. A prospective cohort study with 780 patients were 
conducted for a follow-up period of 4.4 years reported an 
association of decreased LTL with all-cause mortality, with 
an adjusted hazard ratio of 1.8 in the lowest TL quartile 
compared with the highest TL quartile.(137) Moreover, 
LTL has been observed to be shorter in patients with 
premature acute MI (aged <50 years) than in healthy, age-
matched controls.(23) In a clinical study of 803 patients, 
LTL was decreased by approximately 40% in patients with 
heart failure, and TL in the patients with heart failure was 
associated to the disease severity.(138) There was a study 
investigating the association of a lower left ventricular 
ejection fraction with decreased TL, which reported the 
association of one SD decrease in TL with a 5% lower 
ejection fraction.(139) Moreover, LTL was significantly 
associated with cardiovascular outcomes in patients with 
ischemic heart failure (140).
Telomerase as A Therapeutic Target in Cardiovascular Disease
From the implications of current understanding of telomere 
biology, potential therapeutic interventions, such as the 
maintenance of TL and modulation of telomerase activity 
to reverse telomere attrition and cellular senescence, is 
emerging as a new strategy for treating atherosclerosis and 
CVD.(140) 
 Experimental studies have reported that the 
manipulation of telomerase activity and TL enhances or 
reverses senescence and aging-associated phenotypes.(141-
143) For example, the incidence of ischemic heart failure 
in mice can successfully be prevented by the telomerase 
activation therapy after MI. The treatment of adeno-
associated viruses with the cardiac-specific telomerase 
expression resulted in elongated telomeres, attenuated 
cardiac dilation, improved ventricular function, and smaller 
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Figure 5. Schematic overview of telomere length and cardiovascular diseases.(18) (Adapted with permission from Molecular Diversity 
Preservation International)
infarct scars as well as improved the survival by 17% 
compared to the controls.(144)
 The effect of TA-65®, a natural product-derived 
telomerase activator, on metabolic markers and 
cardiovascular health. In addition to apparent positive 
immune remodeling in these patients, TA-65® treatment 
has shown an improvement of metabolic markers with 
a decrease in the fasting glucose, insulin levels, total 
cholesterol and low-density lipoprotein cholesterol. In 
parallel, the systolic and diastolic blood pressures of these 
patients were significantly ameliorated after treatment. These 
results suggest that telomerase activation is a rejuvenation 
strategy for age-associated diseases such as cardiovascular 
diseases and might prove a therapeutic adjunct or alternative 
in this setting.(145) The use of thiazolinediones (TZD) 
may hold real promise for a solution to the differential 
role of telomerase in the intimal and medial layers through 
activation of telomerase in ECs and inhibition of telomerase 
in VSMCs. In the past 15 years, peroxisome proliferator-
activated receptor gamma (PPAR-g), a member of the 
nuclear receptor superfamily, has emerged as an important 
player in vascular protection. PPAR-g is expressed in both 
vascular endothelial and smooth muscle cells, and shown 
to be critically involved in the development of vascular 
complications and inflammation and hypertension.(146-
149) In fact, the anti-proliferative, anti-atherosclerosis 
properties of PPAR-g  have been shown to suppress VSMC 
proliferation, which could be at least in part mediated by 
its effects on suppression of telomerase activity (pro-
proliferation). This is supported by the findings that PPAR-g 
activation suppresses telomerase in cultured VSMC (117).
 Other reports showed that resveratrol, a type of 
natural phenol present in some fruits, activates the catalytic 
subunit of telomerase in human aortic SMC and pulmonary 
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microvascular endothelial cells. Similar observations were 
obtained in resveratrol treated C57BL/6J mouse heart and 
liver tissues.(149) Resveratrol has been shown to produce 
changes associated with longer lifespan, including increased 
insulin sensitivity, PGC-1a activity and mitochondrial 
number.(150) Interestingly, elderly mice fed with resveratrol 
showed a marked reduction in signs of aging with decreased 
inflammation and vascular endothelium senescence, and 
increased aortic elasticity.(126) Despite the facts that the 
exact mechanism by which resveratrol induces TA remains 
unknown, these findings suggest a strong link with its 
beneficial effect in anti-aging processes in cardiovascular 
cells affected by disease.
 In the last few years, another chemical compound, 
AGS-499, has been started to show its neuroprotective 
effects in the amyotrophic lateral sclerosis (ALS) disease 
animal model via increased TA. In vivo treatment with 
AGS-499 has increased significantly TA in these animals 
and improved their life-span.(151) Furthermore, AGS-499 
treatment, without altering their functionality, protected 
stem cells from apoptosis and DNA damage produced 
by long-term exposure to oxidative stress (152). Many 
studies  have  also  demonstrated  that  acute  activation  of 
telomerase using AGS-499 restored NO bioavailability and 
limited ROS production in micro-vessels from subjects with 
CAD.(153)
Conclusion
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